Boston Scientific Sees Unusually High Options Volume (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 65,788 put options on the stock. This is an increase of approximately 205% compared to the average volume of 21,596 put options.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: CHAMPION‑AF trial met all primary and key secondary endpoints for the WATCHMAN FLX versus NOACs — clinical data supports the WATCHMAN franchise and stroke-prevention positioning, which is bullish for long-term device revenues. Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints
• Positive Sentiment: Boston Scientific completed its acquisition of Valencia Technologies — expands product pipeline/technology footprint (supports tuck‑in growth and cross‑sell opportunities). Boston Scientific completes Valencia Technologies acquisition
• Positive Sentiment: Additional clinical/data wins and study support for intravascular ultrasound (IVUS) in PCI underscore minimally invasive care leadership — a structural growth thesis for cardiovascular devices. Boston Scientific study backs use of intravascular ultrasound in PCI
• Neutral Sentiment: Some analysts reiterated positive views (RBC, Needham, Raymond James earlier reaffirmations), and long‑term bull pieces highlight durable growth — supports case for recovery if execution stabilizes. Boston Scientific (NYSE:BSX) Earns “Outperform” Rating from Royal Bank Of Canada
• Negative Sentiment: Raymond James downgraded the stock and cut estimates amid concerns about U.S. electrophysiology trends and Watchman uptake, which triggered a sharp share decline and hurt near‑term sentiment. Raymond James downgrades Boston Scientific but long-term story remains intact
• Negative Sentiment: Unusually large put‑option volume today (put buying jumped ~205%) signals elevated short‑term hedging or bearish bets from traders, adding downside pressure. Options activity report
• Negative Sentiment: Multiple law firms have filed or solicited investors for securities‑fraud class actions tied to allegations about disclosure of electrophysiology volumes and related issues — legal risk and potential litigation costs are headline negatives for sentiment. Bronstein class action notice

Boston Scientific Trading Down 1.2%

Shares of Boston Scientific stock opened at $62.01 on Thursday. Boston Scientific has a 1 year low of $61.24 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The business has a 50 day moving average price of $75.78 and a 200 day moving average price of $89.84. The company has a market capitalization of $92.15 billion, a P/E ratio of 31.96, a P/E/G ratio of 0.97 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the prior year, the firm earned $0.70 EPS. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts anticipate that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BSX. Steph & Co. acquired a new position in shares of Boston Scientific in the third quarter valued at approximately $25,000. Financial Consulate Inc. acquired a new stake in Boston Scientific during the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp boosted its position in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth approximately $26,000. Finally, Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at $26,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Jefferies Financial Group reiterated a “buy” rating on shares of Boston Scientific in a research report on Monday, March 16th. Morgan Stanley decreased their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Mizuho dropped their price objective on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Barclays cut their price objective on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday, February 3rd. Finally, Evercore reduced their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $104.36.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.